Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of JH013 Injection in Patients With Primary Sjögren's Syndrome

NCT07818694 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07818694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07818694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of JH013 Injection in Patients With Primary Sjögren's Syndrome
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 28, 2028
Enrollment
54 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome (pss)